Last reviewed · How we verify
NCT05903911
Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria
NA trial testing Trans Care Web App in Gender Dysphoria in 312 participants. Completed in 19 May 2025.
19 May 2025
Quick facts
| Lead sponsor | University of Wisconsin, Madison |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 312 |
| Start date | 12 December 2024 |
| Primary completion | 19 May 2025 |
| Estimated completion | 19 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Trans Care Web App
Conditions studied
- Gender Dysphoria — all drugs for Gender Dysphoria →
Sponsor
University of Wisconsin, Madison
Who can join
18 and older, any sex, with Gender Dysphoria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The current project aims to improve the well-being of trans and nonbinary (TNB) individuals through an online intervention (Trans Care) targeting the reduction of symptoms of gender dysphoria. The Trans Care intervention will involve the creation of an online intervention comprised of eight modules intended to reduce symptoms of gender dysphoria, increase active coping, and improve the well-being of TNB individuals. Aim 2 is a randomized controlled trial of the proposed intervention and will enroll 260 TNB participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05903911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trans Care Web App
Trials testing the same drug.
- NCT05884307 — Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria · NA · completed
Other recruiting trials for Gender Dysphoria
Currently open trials in the same condition.
- NCT06969326 — Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy · Phase 3 · recruiting
- NCT07147166 — Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affir · NA · recruiting
- NCT06639776 — Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons · recruiting
- NCT06639763 — Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients · recruiting
- NCT06351501 — Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria · Phase 3 · recruiting
Other University of Wisconsin, Madison trials
Trials by the same sponsor.
- NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
- NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
- NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
- NCT07470723 — The ORIGIN-FH Study · NA · recruiting
- NCT06975657 — Well-being Skills for Reentry · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05903911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05903911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing